Docetaxel Impact on Metastastic Prostate cancer patients: a quality of Life Evaluation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29025

Enrollment

300

Registered

2021-02-07

Start date

2021-02-07

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: - Age = 18 year - Prostaatonline-participant (Patients that gave approval (in prostaatonline) for the use of data for scientific purposes) - Treatment with docetaxel during the time of participation in prostaatonline

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Primary endpoint Does the change of QoL differ during the time of treatment with docetaxel with respectively HSPC versus 1st line and 2nd line CRPC?	—

Secondary

Measure	Time frame
Secondary endpoint • What is the change in QoL at the time of treatment with docetaxel in patients with metastatic prostate cancer? • What is de absolute QoL after the last cycle from one series of treatment with docetaxel? • What is de QoL six months after the last docetaxel in one series?	—

Contacts

Public ContactPaul Hamberg

Franciscus Gasthuis & Vlietland

p.hamberg@franciscus.nl010-4617590

Outcome results